Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2015

View Archived Issues

JNJ-54861911: promising drug candidate provides stable Abeta reduction

LPCAT-1 implicated in the evolution and progression of breast cancer

Garvan Institute scientists receive support from the Michael J. Fox Foundation

Ocata Therapeutics licenses iPSC technology from Allele Biotechnology

PET imaging of CD4/sr39tk mice enables in vivo tracking of T cells

Novel radiolabeled anti-PSMA nanobody for detection and treatment of prostate cancer

BioLineRx reports topline data for novel stem cell mobilization treatment

Inception 2 patents dual PPARalpha and -delta antagonists

Alexar Therapeutics presents new LXR-beta modulators

NGM Biopharmaceuticals reports phase II data for NGM-282 in primary biliary cirrhosis

Lupin and Indian Rotary Club launch campaign against tuberculosis

Merck & Co. designs small-molecule inhibitors of Hdm2-p53 interaction

Signum Dermalogix licenses SIG-990 to Dermata Therapeutics

Trelagliptin gains first approval in Japan

Daewoong Pharmaceutical presents novel antifungals

Carna Biosciences discloses novel BTK inhibitors

Roche reports development of CB2 receptor agonists

Cladribine receives U.S. orphan drug designation for neuromyelitis optica

Japan Tobacco describes new RORgamma antagonists

European Commission approves Mysimba for weight management

Japanese approval sought for E Keppra as adjunctive therapy for generalized tonic-clonic seizures

Actelion's Opsumit approved in Japan for pulmonary arterial hypertension

MorphoSys regains rights to MOR-202 from Celgene

Aridis starts clinical development of monoclonal antibody against Pseudomonas aeruginosa

Ebola virus vaccines cAd3-EBOZ and VSV-ZEBOV appear to be safe in phase II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...